What was shown
A real case: 35 years old, four years of unexplained infertility, AMH 2.9, normal FSH/LH, mild male factor — and a prior cycle with 19 oocytes, 4 mature, 79% immature, one euploid embryo, no pregnancy. The talk uses this anchor case to walk through random-start, DuoStim, triple-trigger logic and the protocol moves that turn a high-yield-low-quality cycle into something usable.
Key findings
A 79% immaturity index almost always signals trigger or LH-support failure, not stimulation failure. Random-start protocols allow stimulation initiation at any cycle phase without compromising outcome, especially in oncofertility and time-pressed cycles. DuoStim doubles the oocyte yield per month and recovers cases where a single cycle did not produce a euploid embryo. Triple trigger (agonist + HCG + rLH) targets oocyte maturation in patients with prior maturation failure.
What this means in practice
Review the maturation index before blaming the protocol — high yield with low maturity is a trigger story. Use random-start for time-sensitive cases and DuoStim when a single retrieval underperforms in older patients. Add rLH where prior maturity was low even at adequate FSH dose.
Caveats
Random-start and DuoStim need careful patient counselling on workload and emotional load. Triple trigger increases complexity and cost; reserve for documented prior maturation failure. The luteinisation question with DuoStim — antagonists and progesterone monitoring — is still under debate.
The anchor case — 79% immature oocytes out of 19 retrieved — the speaker reads as a "trigger story," not a stimulation failure: a high yield with low maturity almost always points to trigger or LH-support failure.
Random-start and DuoStim here are tools of time: starting in any cycle phase (important in oncofertility) and two retrievals in a month rescue cases where one retrieval yields no euploid embryo; a triple trigger (agonist + hCG + rLH) targets maturity.
The upshot: before changing the protocol, assess the maturity index; random-start, DuoStim and a reinforced trigger are reserved for specific indications (time, repeat immaturity), with honest counselling of the couple on burden and cost.
Random-start means beginning stimulation regardless of the cycle phase — in the follicular or luteal phase. The approach has proven safe with a comparable yield of mature oocytes, which is critical for oncofertility and time-sensitive situations where waiting for menstruation is not an option.
DuoStim involves two stimulations in one cycle (follicular and luteal waves) to rapidly accumulate oocytes in patients with a reduced reserve. Combined regimens with aromatase inhibitors and gonadotropins, along with a 'triple trigger', help optimize maturation when the oocyte immaturity index is high.
The complex clinical case shows how these tools combine into an individual strategy: the choice of start timing, drug combinations and trigger type is subordinated to a specific goal — the maximum number of competent oocytes in a short time without compromising safety.
A 35-year-old with normal AMH, normal FSH/LH and 4 years of unexplained infertility. Triple trigger, 19 oocytes retrieved — and 79% immaturity. The talk uses real cases to walk through random-start, DuoStim and the role of LH supplementation when standard stimulation hits a wall.
Patients arrive at the clinic already having consulted ChatGPT, and regulators are reviewing the first AI ‘doctors’. What in artificial intelligence already works in reproductive medicine — from assistant avatars to embryo assessment and stimulation personalisation? A live discussion on three levels — strategy, service and clinic — with practical cases and a panel Q&A.
A Sona-Pharm grant award for specialists in infertility treatment. Applications open on 1 February 2027. Ceremony — July 2027, Stockholm, during the ESHRE meeting.
Targeted, biomarker-guided immunotropic therapy in reproductive medicine. A lecture by Kseniia Khazhylenko at the UARM Symposium 2026.
Audio: UASubtitles: UA32 min
-1.png&w=3840&q=75)
